DTIL News and Press, Precision BioSciences Inc. From 04/16/24

- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners ...

2024-04-01 10:00:18 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...

2024-03-27 11:53:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precision BioSciences (NASDAQ: DTIL ) just reported results for the fourth quarter of 2023. Precision BioSciences reported earnings per share of -$3.35. This was below the...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-27 06:51:54 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...

- Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets with Imugene, TG Therapeutics and Caribou Biosciences including nearly $50 million in upf...

2024-03-26 12:16:48 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...

2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish finan...